Jump to content

PNU-120,596

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DePiep (talk | contribs) at 20:11, 2 April 2016 (Remove redundant parameters InChI, InChIKey (StdInChI, StdInChIKey are used). See Talk (via AWB script)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

PNU-120,596
Identifiers
  • 1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)urea
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H14ClN3O4
Molar mass311.720 g·mol−1
3D model (JSmol)
  • COc1cc(OC)c(Cl)cc1NC(=O)Nc2noc(C)c2
  • InChI=1S/C13H14ClN3O4/c1-7-4-12(17-21-7)16-13(18)15-9-5-8(14)10(19-2)6-11(9)20-3/h4-6H,1-3H3,(H2,15,16,17,18) ☒N
  • Key:CEIIEALEIHQDBX-UHFFFAOYSA-N ☒N
 ☒NcheckY (what is this?)  (verify)

PNU-120596 is a drug that acts as a potent and selective positive allosteric modulator for the α7 subtype of neural nicotinic acetylcholine receptors.[1][2] It is used in scientific research into cholinergic regulation of dopamine and glutamate release in the brain.[3][4][5]

References

  1. ^ Hurst, R.; Hajós, M.; Raggenbass, M.; Wall, T.; Higdon, N.; Lawson, J.; Rutherford-Root, K.; Berkenpas, M.; Hoffmann, W.; Piotrowski, D.; Groppi, V. E.; Allaman, G.; Ogier, R.; Bertrand, S.; Bertrand, D.; Arneric, S. P. (2005). "A novel positive allosteric modulator of the alpha7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterization". Journal of Neuroscience. 25 (17): 4396–4405. doi:10.1523/JNEUROSCI.5269-04.2005. PMID 15858066.
  2. ^ Young, G.; Zwart, R.; Walker, A.; Sher, E.; Millar, N. (2008). "Potentiation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site". Proceedings of the National Academy of Sciences of the United States of America. 105 (38): 14686–14691. Bibcode:2008PNAS..10514686Y. doi:10.1073/pnas.0804372105. PMC 2535569. PMID 18791069.
  3. ^ Livingstone, P.; Srinivasan, J.; Kew, J.; Dawson, L.; Gotti, C.; Moretti, M.; Shoaib, M.; Wonnacott, S. (2009). "Alpha7 and non-alpha7 nicotinic acetylcholine receptors modulate dopamine release in vitro and in vivo in the rat prefrontal cortex". The European Journal of Neuroscience. 29 (3): 539–550. doi:10.1111/j.1460-9568.2009.06613.x. PMID 19187266.
  4. ^ Barron, S.; Mclaughlin, J.; See, J.; Richards, V.; Rosenberg, R. (2009). "An allosteric modulator of alpha7 nicotinic receptors, N-(5-Chloro-2,4-dimethoxyphenyl)-N'-(5-methyl-3-isoxazolyl)-urea (PNU-120596), causes conformational changes in the extracellular ligand binding domain similar to those caused by acetylcholine". Molecular Pharmacology. 76 (2): 253–263. doi:10.1124/mol.109.056226. PMC 2713121. PMID 19411608.
  5. ^ Livingstone, P.; Dickinson, J.; Srinivasan, J.; Kew, J.; Wonnacott, S. (2009). "Glutamate-Dopamine Crosstalk in the Rat Prefrontal Cortex is Modulated by Alpha7 Nicotinic Receptors and Potentiated by PNU-120596". Journal of molecular neuroscience : MN. 40 (1–2): 172–176. doi:10.1007/s12031-009-9232-5. PMID 19688191.


Template:Nootropics


Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=PNU-120,596&oldid=713234937"